LOH analysis suggests that multiple tumor suppressor genes play a role in the development of human TCC. The human homolog of the Drosophila PTCH was recently cloned and mapped to the BCNS locus on 9q22.3, a chromosomal region commonly deleted in TCCs. We ®rst examined the steady state mRNA transcription of the PTCH, SMOH and GLI3 genes of the HH signal transduction pathway in TCC cell lines and normal urothelium. Normal urothelium and TCC cell lines express these three genes within the PTCH signal transduction pathway. We then screened for PTCH mutations in`hot spot' exons 6, 8, 13 and 16 by PCR/ SSCP analysis of genomic DNAs from 54 TCC tumor samples and control autologous peripheral blood lymphocytes. DNA sequence analysis con®rmed TCCspeci®c mutations in two of 54 patients (3.7%). These mutations resulted a single amino acid substitution and two frame shifts. One tumor had PTCH mutations in exon 16 as well as exon 13 and one tumor had a mutation in exon 13 alone. Both TCC tumors that contained PTCH mutations had a loss of heterozygosity at 9q. Although the PTCH protein has an unknown function in urothelial cells, the detection of the PTCH, SMOH and GLI3 transcripts in normal urothelium and TCC cell lines and rare PTCH mutations in tumor samples suggest that the HH pathway may have a role in controlling the proliferation of urothelial cells and that PTCH mutations may contribute to the development of a subset of TCCs.
Introduction
Transitional cell carcinoma of the bladder (TCC) is a principle genitourinary lesion with projected incidence of 54 000 new cases and nearly 12 000 cancer related deaths per year (Wingo et al., 1997) . Approximately 25 ± 35% of new cases of TCC present with muscle invasion at the time of diagnosis. Of the remaining cases of super®cial disease, 10 ± 20% of patients progress to a muscle invasive state in an unpredictable fashion (Malkowicz and Wein, 1994; Catalona, 1988) .
A better understanding of the genetic changes underlying the phenotypic expression of TCC has developed over the last 6 years and a number of speci®c genes and loci on chromosomes 3, 9, 11, 14, 17 and 18 have been implicated in TCC tumorigenesis (Knowles et al., 1994; Li et al., 1996; Ruppert et al., 1993; Orlow et al., 1994; Chang et al., 1995; Brewster et al., 1994; Spruck et al., 1994; Linnenbach et al., 1993) . A loss of heterozygosity (LOH) on the long arm of chromosome 9 is the most frequent genetic alteration in both super®cial and invasive TCC (Linnenbach et al., 1993; Spruck et al., 1994) . Two regions of deletion have been localized on 9q, one of which may include the human homolog of the Drosophila hedgehog receptor, the PTCH gene (Habuchi et al., 1995) .
Drosophila PTCH is a segment polarity gene required for the correct patterning of larval segments and imaginal discs during¯y development (Hooper and Scott, 1989) . Based on various studies, PTCH has been found to be a membrane spanning protein and to be a component of the morphogen, hedgehog (Hh) signaling pathway (Hooper and Scott, 1989; Chen and Struhl, 1996) . The complete human PTCH gene has recently been cloned, sequenced and found to be within the candidate region for the basal cell nevus syndrome (BCNS) also known as Gorlin syndrome (Gorlin, 1987; Hahn et al., 1996a; Johnson et al., 1996) . Human PTCH gene encodes a putative protein of 1296 amino acids and displays 67% identity at the nucleotide level and 60% similarity at the amino acid level to the Drosophila PTCH gene. The genomic sequence of the human PTCH gene spans approximately 34 KB and encompasses 23 exons and maps to human chromosome region 9q22.3 (Hahn et al., 1996a,b; Johnson et al., 1996) . Familial and sporadic basal cell carcinoma of the skin (BCC) display a loss of heterozygosity in this region. These ®ndings led to the detection of mutations throughout the entire PTCH gene in BCNS and sporadic BCC Hahn et al., 1996b; Gailani et al., 1996) . A low incidence of PTCH mutations have been found in sporadic medulloblastoma, meningiomas, breast carcinoma and esophageal squamous cell carcinoma (Xie et al., 1997; Rael et al., 1997; Maesawa et al., 1998) .
The purpose of this study was to examine the role of the PTCH gene in TCC. First, we examined the steady state transcription of the PTCH, SMOH and GLI3 genes by RT ± PCR in normal bladder mucosa, normal human smooth muscle, normal human kidney, nine dierent TCC cell lines, a super®cial and an invasive TCC. We then screened 54 uncultured TCCs and autologous peripheral blood lymphocytes for PTCH gene mutations by PCR/SSCP and DNA sequence analyses of exons 6, 8, 13 and 16, which have been previously identi®ed as`hotspot' exons in BCNS and sporadic BCC Hahn et al., 1996b; Gailani et al., 1996; Chidambaram et al., 1996; Unden et al., 1996) .
Results
Steady state expression of the PTCH, SMOH and GLI3 transcripts in the human bladder
We found that the PTCH transcript was present in normal human bladder mucosa, a super®cial TCC cell line, an invasive TCC cell line, two super®cial TCC tissues and one invasive TCC tissue (Figure 1 ). We also found that the mRNA for PTCH is also expressed in normal urothelial cells, normal kidney and normal smooth muscle cells (data not shown). Additionally, the SMOH and GLI3 transcripts were present in normal human bladder mucosa, a super®cial TCC cell line, an invasive TCC cell line, two super®cial TCC tissues and one invasive TCC tissue (Figure 1 ). We have been unable to detect the expression of GLI1, GLI2, Sonic Hedgehog or Indian Hedgehog in human bladder or transitional cell carcinoma of the bladder (data not shown).
Mutational analysis by PCR/SSCP of the PTCH gene
The 54 TCC specimens in this study (2 T0, 15 Ta, 10 T1, 10 T2, 11 T3 and 6 T4) were examined for mutations in exon 6, 8, 13 and 16 of the PTCH gene by PCR/SSCP. We found that there were no band shifts observed in exon 6 and 8 of the PTCH gene (data not shown). We detected one bandshift in exon 16 in an invasive tumor #7 (Figure 2 ). The mutation in exon 16 is an insertion of a cytosine at bp 2708 resulting in a frameshift ( Table 1 ). The genomic DNA from this tumor sample had an additional band shift in exon 13 (Figure 3 ). The mutation in exon 13 is a single Figure 1 The expression of PTCH, SMOTH, GL13 and the cell cycle related gene, GADD45 in human normal bladder mucosa, two human transitional cell carcinoma cell lines, two super®cial bladder tumors and one invasive bladder tumor. Each PCR reaction product was run on a 1.5% TBE agarose gel and stained with ethdium bromide. Lanes 1 and 14, 100 bp marker; lanes 2 ± 5, normal bladder mucosa; lanes 6 ± 9, RT4 TCC cell line; lanes 10 ± 13, UMUC-3 TCC cell line; lanes 15 ± 18, an invasive TCC tumor; lanes 19 ± 22, a super®cial TCC tumor; lanes 23 ± 26, a super®cial TCC tumor. Lanes 2, 6, 10, 15, 19 and 23, GADD45; lanes 3, 7, 11, 16, 20 and 24, PTCH; lanes 4, 8, 12, 17, 21 and 25, SMOTH; lanes 5, 9, 13, 18, 22 and 26, GLI3 base pair substitution of a guanine for a cytosine resulting in a nonconserved amino acid substitution of an arginine for an alanine. Another invasive TCC tumor (tumor #5) had a bandshift in exon 13 ( Figure  3 ). Tumor #5 had an insertion of adenine at bp 2028 resulting in a frameshift. The two tumors that had mutation(s) in the PTCH gene also had a loss of heterozygosity at 9q (Linnenbach et al., 1993) .
Discussion
Various studies have implicated the HH ± PTCH pathway in BCC development, however little is known about the role of the HH ± PTCH pathway in the human bladder. We have shown using two dierent primer pairs that the PTCH transcript is present in normal human urothelium, normal bladder mucosa, normal kidney, human smooth muscle cells, various TCC cell lines, in a super®cial and in an invasive TCC. A signal transduction mechanism has been proposed in which HH binds to PTCH which then induces Smoothened (SMOH) activity (Stone et al., 1996) . SMOH is a seven-pass membrane protein which is thought to transduce a signal that up regulates Decapentaplegic (Dpp) and Wnt families of signaling proteins as well as PTCH (Alcedo et al., 1996) . On the other hand, normal PTCH is a transcriptional regulator and down regulates the expression of SMOH. Recent studies using both Northern blotting and in situ hybridization have reported that sporadic and familial BCCs overexpress a dysfunctional, mutated PTCH gene (Gailani et al., 1996; Kallassy et al., 1997; Unden et al., 1997) . The over expression of the mutated PTCH mRNA would be presumably due to the loss of PTCH autoregulatory mechanisms (Marigo et al., 1996) . Not surprisingly, overexpression of SMOH has been observed in human BCC (Kallassy et al., 1997) . We have shown that human normal bladder, TCC cell lines and various bladder tumors express SMOH.
Activated SMOH down regulates a cAMPdependent protein kinase A (PKA), presumably by decreasing cAMP levels. The result is to activate the Cubitus Interruptus (CI) zinc ®nger transcription factor, the human homologue is the oncogene GLI1 which then induces various target genes (Dominguez et al., 1996; Hepker et al., 1997; Kinzler et al., 1987 Kinzler et al., , 1988 . We have detected the expression of GLI3 (a putative negative transducer) in normal bladder as well as bladder carcinoma but we have been unable to detect GLI1 or GLI2 transcripts (data not shown). Recently, three out of 47 sporadic BCC were found to contain activating SMOH mutations which lead to overexpression of SMOH/PTCH and the downstream transcription factor, GLI1 (Dahmane et al., 1997; Xie et al., 1998) . The SMOH gene is located on chromosome 7q31-32 and is composed of 12 exons. Polysomy of chromosome 7 has been reported in TCC and The open arrow points to the location of a missing band in tumor #7 which is present in normal and other TCC samples mutational activation of SMOH in TCC also can not be ruled out (Waldman et al., 1991) . However, quanti®cation of PTCH and SMOH transcript levels may better identify an abnormal PTCH signal transduction pathway in bladder carcinoma.
The 54 TCC specimens in this study (17 Ta, 10 T1, 10 T2, 11 T3 and 6 T4) were examined for mutations in exon 6,8,13 and 16 of the PTCH gene by PCR/SSCP. Each tumor DNA was compared to lymphocyte DNA from the same patient for each exon and each bandshift was found to be unique to each tumor DNA indicating that the bandshifts were mutations rather than polymorphisms. The mutations found in the PTCH gene in TCC tumors are summarized in Table 1 . The sequence changes in the PTCH gene were predominantly changes predicted to result in truncated proteins. The product of the PTCH gene is a large glycoprotein predicted to have 12 membrane-spanning domains with exon 13 encoding a region in the small intracellular domain and exon 16 encoding a part of a second large extracellular loop (Gailani et al., 1996) . Two invasive TCC tumors had mutations in exon 13 and one of these invasive TCC tumors had an additional mutation in exon 16. A similar phenomenon of PTCH mutations in two dierent exons has been reported in two dierent patients with BCC (Chen and Struhl, 1996) . Consistent with the two-hit hypothesis for the inactivation of a tumor suppressor locus, both TCC tumors that contained mutations in PTCH in the present study were previously shown to have a loss of heterozygosity at 9q (Linnenbach et al., 1993) .
The three PTCH mutations that we have found in two invasive TCC implies that the HH pathway has a role in the development of TCC. However, given the time consuming eorts in analysing all 23 exons, a true understanding of the role of PTCH mutations in the development or progression of TCC awaits further analysis. Our ®ndings dier slightly from a mutational analysis of the PTCH in TCC reported recently (Xie et al., 1997; Simoneau et al., 1996) . In one study, the analysis of 20 primary bladder tumors had excluded 9q22.3 as the`de®ned area of proximal deletion' and showed that there were no PTCH mutations in these tumors (Simoneau et al., 1996) . In another survey of 14 primary bladder tumors, these investigators found that three primary bladder tumors had LOH at a microsatellite that was derived from intron 1 of the PTCH gene, however this group did not detect any mutations in the PTCH gene (Xie et al., 1997) . These ®ndings seem to indicate that either the incidence of PTCH mutations is rare in TCC or the detection is limited by the ability of SSCP or heteroduplex analysis. Gailani et al. (1996) reported inactivating mutations in two BCC tumors that did not show LOH or variants on SSCP. The size limit generally accepted in PCR/SSCP is 250 base pairs. We took various measures to optimize conditions accordingly (Unden et al., 1997) . For example, we used Sau3A to enzyme digest exon 13 to shorten the size of the product. All the band shifts that were observed in exon 13 were found through sequencing to be mutations.
High levels of PTCH induced by HH sequester any free HH and limits further diusion of HH (Chen and Struhl, 1996) . Mammals have been found to express three dierent hedgehog genes, sonic (SHH), Indian (IHH) and Desert (DHH) (Marigo et al., 1995) . Thus far, we have not found by RT ± PCR, the SHH transcript in normal urothelium and the TCC cell lines (data not shown). IHH appears to be expressed at least in adult liver and kidney, however we have not detected IHH in human bladder mucosa (Marigo et al., 1995) . Recently a transgenic mouse was developed which over expresses the SHH gene in the skin and embryos and neonates had skeletal and skin abnormalities similar to what is observed in BCNS with perinatal lethality (Oro et al., 1997) . In addition, a mutation in the SHH gene has been reported in a BCC tumor (Oro et al., 1997) . However, one report suggests that there is most probably an amplifying/ autocrine loop in BCC in that Sonic/Indian/Desert HHs are rarely expressed in BCC (Kallassy et al., 1997) . On the other hand, in another study, SHH was found to be expressed in normal human hair follicles and in *45% of BCC (Dahmane et al., 1997) .
In summary, we have found three PTCH mutations in 3.7% of TCC samples from 54 patients. Since we examined only`hotspot' exons, there are potential additional PTCH mutations in TCCs that we had previously found to contain LOH on 9q. While we have shown that PTCH mutations do occur in a subset of TCC, other unknown tumor suppressor genes may be located on 9q, especially at 9q34 (Habuchi et al., 1997) . However, the presence of PTCH, SMOH and GLI3 transcripts in human bladder and bladder tumors indicate that the PTCH signal transduction pathway bears additional investigation as part of an apparatus that controls the proliferation of the normal and transformed urothelium.
Materials and methods

Tissue culture
Nine TCC cell lines (RT4, SW780, 5637, HT-1376, TCC SUP, HT-1197, UMUC-3, J82 and T24) were obtained from the American Type Tissue Collection (Rockville, MD) and grown routinely in MEM (Gibco ± BRL, Grand Island, NY) supplemented with 10% fetal calf serum (FCS) (Intergen, Purchase, NY), nonessential amino acids (Gibco ± BRL) and penicillin-streptomycin-fungizone (Gibco ± BRL). Human urothelial cells and human smooth muscle cells were derived from ureteral urothelial explants from transplant donors or ureters from patients with low grade renal cell carcinomas. The human urothelial cells were maintained in keratinocyte growth media (containing epidermal growth factor and bovine pituitary extract) (Gibco ± BRL). The human smooth muscle cells were grown routinely in MEM + 10% FCS.
Isolation of total RNA from tumor cell lines or tumor tissue
Fresh tissue from transurethral resection of bladder tumors or cystectomy specimens was obtained from the Department of Urology, University of Pennsylvania and¯ash frozen in liquid nitrogen. Total RNA was extracted from cultured tumor cell lines or from frozen tissue by the single-step method of Chomczynski and Sacchi (1987) or the modi®ed single-step method using Tri-reagent (Chomczynski, 1993) . For the single step method, brie¯y, a denaturing solution (4 M guanidinium thiocyanate, 2.5 mM sodium citrate, pH 7.0, 0.5% sarcosyl and 0.1 M b-mercaptoethanol) was added directly to¯asks of growing cells or to pulverized frozen tissue. The frozen tissue was then homogenized and the cells or tissue added to RNasefree eppendorf tubes. Sodium acetate (2 M, pH 4.0), buered phenol and chloroform/isoamyl alcohol were then added to the cells or tissue. The mixture was shaken and placed on ice for 10 min. The tube was centrifuged at 48C at 12 000 r.p.m. and the aqueous phase containing the RNA was transferred to a fresh tube and mixed with 0.6 vol of isopropanol. If necessary, some RNA samples were treated with RNase-free DNase (Promega, Madison, WI).
Reverse transcription-polymerase chain reaction (RT ± PCR)
A master mix for reverse transcription was prepared containing MgCl 2 (a ®nal concentration of 5 mM), 106PCR buer (50 mM KCI and 10 mM Tris-HCl, pH 8.3), dNTPs (1 mM of each dNTP), (4) RNase inhibitor (1 unit/ml), (5) Diethyl pyrocarbonate-treated water, and MuLV reverse transcriptase (2.5 units/ml) (Perkin-Elmer, Norwalk, CT). Oligo d(T) 16 (2.5 mM) was added along with the RNA (51 mg of total RNA). The 20 ml mixture was incubated at room temperature for 10 min and then at 428C for 1 h. The reaction was heated at 958C to inactivate reverse transcriptase activity and then cooled to 48C. Primers were used to amplify cDNA of the following genes: (1) PTCH gene ± bp 2622 (upstream primer, 5'-CGATGGAGTCCTTGCCTACAAACTC-3') to bp 3270 (downstream primer, 5'-CACTCCTATGCCAACAGAA-GCGAT-3'); (2) SMOH gene ± from bp 392 (upstream primer, 5'-TGCCCAGTGTGAGAATGACCG-3') to bp 942 (downstream primer, GCAGGACAGAGTCTCATTG-GAGG-3'); (3) GLI3 gene ± from bp 448 (upstream primer, 5'-CATCCTCCTGTACCAATTGATGCC-3') to bp 1028 (downstream primer, 5'-AGCCACTTGCTGAAGAGC-TGCTAC-3'); and (4) GADD45 gene (used as a positive control) ± from bp 415 (upstream primer, 5'-ACCAAACT-GATGAAGTCCTTGCTGTC-3') to bp 747 (downstream primer, 5'-CAGCCAAAGGTCACAGAAGTAATTTC-3') of the GADD45. All primers were obtained from the gene sequences submitted to GenBank.
For each sample, a master mix of 78 ml was prepared, containing 25 mM MgCl 2 106PCR buer (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 0.5 ml of AmpliTaq DNA polymerase and 0.25 ml of [a-32 P]dCTP. 0.15 mM of each primer pair, 0 ± 10 ml of the cDNA and water was added to the master mix and 30 cycles of PCR performed with a ®nal extension step of 728C for 10 min. Annealing temperatures were dependent on the melting temperatures of each primer pair. PCR products were run on an 1.2% agarose gel.
Mutational analysis by PCR/SSCP of the PTCH gene
Fresh tissue was obtained from the Departments of Pathology and Urology at the University of Pennsylvania. Genomic DNA was extracted from fresh tissue and established cell lines. Brie¯y, whole tissue was frozen in liquid nitrogen and crushed to a ®ne powder with a mortar and pestle. Cells were trypsinized and pelleted by centrifugation. Digestion buer (100 mM NaCl, 10 mM Tris-HCL (pH 8.0), 25 mM EDTA, 0.5% SDS and 0.1 mg/ml of Proteinase K) was added to the tissue sample or cell pellet and incubated for 12 ± 18 h at 508C (Goelz et al., 1985) . Each sample was extracted in phenol/ chloroform/isoamyl alcohol and the genomic DNA precipitated in 7.5 M ammonium acetate (33% volume) and 100% ethanol (2.56volume) (Glavac and Dean, 1993) .
Primers used to amplify exons of PTCH were as follows: (1) Exon 6 (upstream primer, 5'-CCTACAAGGTGGATG-CAGTG-3' and downstream primer, 5'-TTTGCTCTCCA-CCCTTCTGA-3'); (2) Exon 8 (upstream primer, 5'-GAG-GCAGTGGAAACTGCTTC-3' and downstream primer, 5'-TTGCATAACCAGCGAGTCTG-3'); (3) Exon 13 (upstream primer, 5'-GTCAGCAGACTGATTCAGGT-3' and downstream primer, 5'-AAGATGAGAGTGTCCACTTTCG-3') and (4) Exon 16 (upstream primer, 5'-AACCCCATTCT-CAAAGGCCTCTGTTC-3' and downstream primer, 5'-CACCTCTGTAAGTTCCCAGACCT-3') (17).
PCR/SSCP was performed according to the method of Sameshima (1992) . PCR was performed for 30 ampli®cation cycles (the annealing temperature was calculated from the melting temperature of each set of primers) with [a-32 P]dCTP (3000 Ci/mmol) followed by a 10 min extension at 728C. The PCR product from exon 13 was digested with the restriction enzyme, Sau 3A (New England BioLabs, MA), due to the sensitivity of SSCP to length of the PCR product. PCR products were diluted tenfold with a solution containing 95% formamide, 20 mM EDTA and 0.05% bromophenol blue. Five microliters of diluted sample was heated at 808C for 2 min and electrophoresed on a 6, 8 or 10% nondenaturing polyacrylamide gel with or without 5 ± 10% glycerol. The electrophoresis was performed with 30 W for 2 ± 12 h. Gels were dried and exposed to Kodak X-OMAT AR X-ray ®lm (Sigma) for a minimum of 24 h. PCR/SSCP was performed on each sample at least in triplicate.
Sequencing analysis
To con®rm a possible mutation in the PTCH gene, the PCR product and gene speci®c sense and antisense primers were denatured by heating to 1008C for 3 min then cooled in an ice-water bath and the sense and antisense strands directly sequenced separately according to the dideoxy sequencing method. Sequencing was performed on PCR products from multiple dierent samples from the same tumor tissue. The tumor sequence was then compared to the sequenced normal PCR product from PBL from the same individual.
